<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03992937</url>
  </required_header>
  <id_info>
    <org_study_id>VMP vs LNG</org_study_id>
    <nct_id>NCT03992937</nct_id>
  </id_info>
  <brief_title>Vaginal Micronized Progesterone Versus Levonorgestrel for Treatment of Non-atypical Endometrial Hyperplasia</brief_title>
  <official_title>Vaginal Micronized Progesterone or Levonorgestrel-releasing Intrauterine System (LNG-IUS) for Treatment of Non-atypical Endometrial Hyperplasia: A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kocaeli University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kocaeli University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of the vaginal micronized progesterone
      and Levonorgestrel-releasing Intrauterine System for treatment of non-atypical endometrial
      hyperplasia in premenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vaginal use of micronized progesterone in the treatment of endometrial hyperplasia can result
      in better than oral administration, as it will remain away from the first pass effect, and
      depending on the local application. In this study, we aimed to compare this local treatment
      with Levonorgestrel-releasing Intrauterine System for treatment of non-atypical endometrial
      hyperplasia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regression and remission rate of endometrial hyperplasia</measure>
    <time_frame>3 month</time_frame>
    <description>Endometrial sampling will be performed for 3'th month with Carmen canula. Pathological specimens will be reported by the specialist pathologist in accordance with the World Health Organisation (WHO) endometrial hyperplasia classification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Reduction From Baseline in Menstrual Blood Loss</measure>
    <time_frame>6 month</time_frame>
    <description>Menorrhagia Impact Questionnaire (MIQ). This is a validated disease-specific patient-reported outcome questionnaire assessing menstrual blood loss and the influence of heavy menstrual bleeding on quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with adverse events associated with medication and device</measure>
    <time_frame>6 month</time_frame>
    <description>Any side effects will be recorded into questionnaire during a consultation with the patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Endometrial Hyperplasia Without Atypia</condition>
  <arm_group>
    <arm_group_label>Vaginal Micronized Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months. With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LNG-IUS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day with one year follow up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal Micronized Progesterone</intervention_name>
    <description>Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months.</description>
    <arm_group_label>Vaginal Micronized Progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Levonorgestrel-Intrauterine System</intervention_name>
    <description>Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day.</description>
    <arm_group_label>LNG-IUS</arm_group_label>
    <other_name>Mirena</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal Patients

          -  Patients with histologically confirmed endometrial hyperplasia without atypia

        Exclusion Criteria:

          -  Endometrial hyperplasia with atypia

          -  Endometrial Carcinoma

          -  Suspected pathology on Physical/Ultrasonographic Examination e.g. fibroids, adnexal
             abnormality
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Şener Gezer, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kocaeli University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Şener Gezer, M.D</last_name>
    <phone>+902623037039</phone>
    <email>dr.senergezer@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kocaeli University</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Şener Gezer</last_name>
      <phone>2623037039</phone>
      <email>dr.senergezer@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Tasci Y, Polat OG, Ozdogan S, Karcaaltincaba D, Seckin L, Erkaya S. Comparison of the efficacy of micronized progesterone and lynestrenol in treatment of simple endometrial hyperplasia without atypia. Arch Gynecol Obstet. 2014 Jul;290(1):83-6. doi: 10.1007/s00404-014-3161-4. Epub 2014 Feb 1.</citation>
    <PMID>24488582</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kocaeli University</investigator_affiliation>
    <investigator_full_name>Şener Gezer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

